![](/upload/201910/11/201910111612332656.jpg)
MSI Detection Kit
Features
■ Accurate:
Containing all NCI recommended mononucleotide locus, highly sensitive and specific.
■ Convenient:
Single-tube amplification, applicable for automatic and batched detection.
■ Fast:
Get results within 6 hours.
Loci detected
![](/upload/201910/11/201910111613418906.png)
Interpretation standard
![](/upload/201910/11/201910111613518750.png)
Workflow
![](/upload/201910/11/201910111614045469.jpg)
Instrument
Gene analyzer (ABI PRISM 310, 3100 Genetic Analyzer, or ABI 3130 Series, 3500 Series, 3730 Series Genetic Analyzer)
Application
NCCN clinical practice guidelines in Oncology: colon cancer(2019.V2)
Universal MMR or MSI testing is recommended in all patients with a personal colon/rectal cancer to identify individuals with Lynch syndrome.
Stage II MSI-H colon/rectal cancer patients may have a good prognosis and do not benefit from 5-FU adjuvant therapy.
For patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors, nivolumab or pembrolizumab added as treatment options in subsequent therapy for patients appropriate for intensive therapy.
※Reference:
NCCN clinical practice guidelines in Oncology: colon cancer(2019.V21)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm
※For research use only